# RAB39B: A novel biomarker for acute myeloid leukemia identified via multi-omics and functional validation

## TL;DR

This study identifies RAB39B as a potential biomarker for acute myeloid leukemia through multi-omics analysis and lab experiments.

## Contribution

RAB39B is newly identified as a potential biomarker for AML with functional relevance to cell growth and death.

## Key findings

- AML shows elevated RAB39B expression compared to normal cells.
- RAB39B is significantly expressed in AML cell lines.
- RAB39B is linked to AML cell growth and programmed cell death.

## Abstract

The objective of this research was to investigate the involvement of RAB39B in acute myeloid leukemia (AML) using bioinformatics analysis and in vitro experiments for validation.

In this article, RNA sequencing data from The Cancer Genome Atlas and genotype-tissue expression were utilized to analyze the expression of RAB39BA and identify differentially expressed genes.

AML exhibited elevated expression of RAB39B in diverse tumor types. In laboratory experiments, it has been demonstrated that RAB39B exhibits a significant expression level in AML cell lines when compared to normal peripheral blood monocytes. Moreover, RAB39B is closely linked to the growth and programmed cell death of AML cells.

In conclusion, RAB39B shows potential as a biomarker for the identification and prediction of AML, contributing to the growth and cell death processes in AML.